金吾财讯 | 诺和诺德(NVO)盘前涨超3%，截至发稿，报67.13美元。消息面上，诺和诺德王牌单品司美格鲁肽总销售量跃升全球首位，超过默沙东的帕博利珠单抗，暂时坐上全球“药王”宝座。彼时在2024年，司美格鲁肽距离K药还有2亿美元的差距。而礼来也不甘落后，2025年第一季度，其美国肠促胰岛素类似物市场总处方量占比增至53.3%，超过诺和诺德。
Source Link金吾财讯 | 诺和诺德(NVO)盘前涨超3%，截至发稿，报67.13美元。消息面上，诺和诺德王牌单品司美格鲁肽总销售量跃升全球首位，超过默沙东的帕博利珠单抗，暂时坐上全球“药王”宝座。彼时在2024年，司美格鲁肽距离K药还有2亿美元的差距。而礼来也不甘落后，2025年第一季度，其美国肠促胰岛素类似物市场总处方量占比增至53.3%，超过诺和诺德。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.